Stock IVA INVENTIVA
Add to a list
To use this feature you must be a member
Log inSign up

News Inventiva

Equities

IVA

FR0013233012

Market Closed - Euronext Paris
Other stock markets
 11:29:46 2024-05-14 am EDT 		After market 11:47:27 am
3.44 EUR +1.18% Intraday chart for Inventiva 3.443 +0.09%
May. 13 Inventiva: additional Phase 2 results in NASH CF
Apr. 22 Inventiva: UBS Group falls below 5% threshold CF

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Inventiva : Notice of meeting to the Ordinary and Extraordinary General Meeting dated June 20, 2024 - Form 6-K
PU
Inventiva: additional Phase 2 results in NASH
CF
Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor
GL
Inventiva : Présentation corporate avril 2024
PU
Inventiva: UBS Group falls below 5% threshold
CF
Transcript : Inventiva S.A. - Special Call
Canaccord Genuity Adjusts Price Target on Inventiva to $20 From $12, Maintains Buy Rating
MT
INVENTIVA : Canaccord Genuity raises target
CF
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F
GL
Transcript : Inventiva S.A., 2023 Earnings Call, Mar 28, 2024
Inventiva announces the nomination of Andre Turenne as Director
GL
Inventiva S.A. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Inventiva reports its 2023 full-year results
GL
Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results
GL
ADRs End Flat, Ehang Holdings Ltd. Climbs 15.6%
DJ
Transcript : Inventiva S.A. - Special Call
Inventiva: positive results from phase 2 clinical trial
CF
Inventiva S.A. Announces Positive Results from the Phase II, Legend, Proof-Of-Concept Study Combining Lanifibranor with Empagliflozin
CI
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D
GL
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IVA Stock
  4. News Inventiva
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW